Objective
The aim of this study was to identify epigenetic factors that are
implicated in the pathogenesis of rheumatoid arthritis (RA) and to explore
the therapeutic potential of the targeted inhibition of these factors.
Methods
PCR arrays were utilized to investigate the expression profile of
genes that encod key epigenetic regulator enzymes. Mononuclear cells from RA
patients and mice were monitored for gene expression changes, in association
with arthritis development in murine models of RA. Selected genes were
further characterized by quantitative real-time PCR, Western blot and flow
cytometry methods. The targeted inhibition of the upregulated enzymes was
studied in arthritic mice.
Results
A set of genes with arthritis-specific expression was identified by
the PCR arrays. Aurora kinase A and B, both of which were highly expressed
in arthritic mice and treatment naïve RA patients, were selected for
detailed analysis. Elevated Aurora kinase expression was accompanied with an
increased phosphorylation of histone H3, which promotes proliferation of T
lymphocytes. Treatment with VX-680, a pan-Aurora kinase inhibitor, promoted
B cell apoptosis, provided significant protection against the onset, and
attenuated the inflammatory reactions in arthritic mice.
Conclusions
Arthritis development is accompanied the changes in the expression of
a number of epigenome-modifying enzymes. Drug-induced downregulation of the
Aurora kinases, among other targets, seems to be sufficient to treat
experimental arthritis. Development of new therapeutics that target the
Aurora kinases can potentially improve RA management.